Only 14 pages are availabe for public view
Metastatic breast cancer (MBC) is still incurable, but it is treatable so goals of therapy are; palliation of symptoms, delay of disease progression, and prolongation of overall survival time without impairing quality of life.
Metastatic disease is the main underlying cause of death in the majority of breast cancer patients and represents a great challenge
60 – 70% of breast cancers have estrogen and /or progesterone receptors, 15-20% are HER2 +Ve and Triple -Ve breast cancer make up about 15%.
5-Year survival rates for MBC is 22% as reported by American cancer society.
Triple –Ve breast cancer and HER2+Ve are the most aggressive types associated with shortened overall survival. But, now a days survival is greatly improved due to appearance of targeted therapy especially in HER2+Ve breast cancer.
This study is a retrospective analysis studying 73 female patients with invasive metastatic breast cancer presented to Clinical oncology department at Ain-Shams University hospitals & El-Matarya teaching Hospital. All patients’ records in the period from January 2014 to December 2016 were reviewed .
Survival analysis was performed using Kaplan- Meier method for overall survival (OS) .
In our study, patients with HER2/neu-positive metastatic breast cancer treated with targeted therapy had superior survival, their mean overall survival is 28 months (95% CI 21-34.8) when compared with those who did not receive targeted therapy, mean overall survival is 12,8 months (95% CI 9- 16.6) & with women with triple-negative breast cancer mean overall survival for Triple negative group is 21 months (95% CI 15.7-26.58).
Trastuzumab was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in the overall prognosis for patients with HER2-positive metastatic disease and this is proven in our study.
Results of multivariable proportional hazards analyses confirmed the independent significant effects of targeted therapy (HR 2.2, 95% CI 1.17- 4.15, P. 014), Brain metastases (HR 0.36, 95% CI 0.16-82, p 0.015) & Performance status (HR. 097, 95% CI. 021-. 446, P 0.003)